Dopamine elevation matters in schizophrenia, and most current antipsychotic medications aim at lowering activity of this neurotransmitter. Unfortunately, this is the wrong approach for schizophrenics with different brain chemistry.
The post 042 Biomedical Markers Bipolar & Schizophrenia Dr Walsh-3 appeared first on CoreBrain Journal.